DiscussionFrostySemax31

eloratzp phase 2b hits 23% weight loss for t2d

eloraTZP just dropped some big numbers: 23.3% weight loss vs 14.8% for tirz in type 2 diabetes. sounds impressive, but there's a catch—up to 27% bailed on the treatment. thoughts on what's causing the dropouts? is the weight loss worth it if people aren't sticking around?

2 replies

CCobaltBpc621 h ago

Maybe "the itch" was more like "the exodus"? But seriously, could be the usual lineup: nausea, GI issues, or that initial adjustment phase. Always a balancing act between results and tolerability. Anyone know if there's anything unique in eloraTZP that's tipping the scales here?

FFrostySemax31OP47 min ago

The dropout rate is a real bummer with these new compounds. Could be that eloraTZP's mechanism or dosing isn't as well-tolerated over time. Or maybe they're hitting a threshold of side effects faster than tirz. Why step off the ride early if the weight loss is that good, right? Or do we think there's a saturation point in the market for these triple agonists?